Mayo Clinic Laboratories > Neurology > Autoimmune > Myasthenia gravis and Lambert-Eaton syndrome

Myasthenia gravis and Lambert-Eaton syndrome

An algorithmic testing approach to expediate diagnosis and treatment

Mayo Clinic-led research supports an optimized diagnostic approach that incorporates autoantibody profiles to screen for and confirm presence of myasthenia gravis (MG) and Lambert-Eaton syndrome (LES). 

Our first-line MG and LES evaluation examines levels of acetylcholine receptor binding antibodies (AChR-Bi). Utilizing a unique human muscle reagent, in which live cells mimic the neuromuscular junction where antibody interaction occurs, this test enables the highest testing sensitivity by providing the lowest cut-off values of receptor binding antibodies. If positive, confirmatory testing measures levels of acetylcholine receptor modulating antibodies (AChR-Mo). In cases where AChR-Bi antibodies are not found, testing automatically reflexes to muscle-specific kinase (MuSK) antibody testing.

Myasthenia gravis and Lambert-Eaton syndrome Test menu

Myasthenia gravis and Lambert-Eaton syndrome

Key testing

Advantages

  • Provides higher specificity, sensitivity, and fewer false positives.
  • Minimizes avoidable CT scans.
  • Reduces unnecessary thymectomy and immunotherapy.
  • Decreases cost and turnaround time by eliminating unnecessary testing.

Highlights

INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.